Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
Zacks News
Aptose Biosciences (APTO) Surges: Stock Moves 9.8% Higher
by Zacks Equity Research
Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up
by Zacks Equity Research
Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.
Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug
by Zacks Equity Research
The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.
This September Could Be Different: 5 Stocks to Buy
by Tirthankar Chakraborty
In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.
Major Indexes Erase Pandemic-Led Losses: 5 Top Picks
by Sreoshi Bera
Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most
Emergent Biosolutions (EBS) Up 21.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo
by Zacks Equity Research
Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.
Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes
by Zacks Equity Research
Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.
Alnylam's Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
Here's Why Hold Strategy is Apt for Acadia Healthcare Stock
by Zacks Equity Research
Acadia Healthcare (ACHC) continues to benefit from increasing demand for telehealth services, strategic buyouts and solid financial position.
Amarin (AMRN) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio
by Zacks Equity Research
ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.
Centene's Contract Renewal to Aid Medicaid Members in Indiana
by Zacks Equity Research
Centene's (CNC) subsidiary MHS gets a contract renewal through which it will be able to efficiently serve its Medicaid members in Indiana.
Encompass Health Forms JV to Efficiently Serve South Carolina
by Zacks Equity Research
Encompass Health (EHC) and MUSC Health intend to offer improved healthcare services in South Carolina through a joint venture.
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
by Zacks Equity Research
Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.
Emergent BioSolutions' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.
Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline
by Zacks Equity Research
Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.
Unity Biotechnology (UBX) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher
by Zacks Equity Research
Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Looking for a Growth Stock? 3 Reasons Why Emergent Biosolutions (EBS) is a Solid Choice
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.
Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod
by Zacks Equity Research
Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.